The estimated Net Worth of Asa Abeliovich is at least $58.4 Million dollars as of 30 December 2020. Asa Abeliovich owns over 125,793 units of Prevail Therapeutics Inc stock worth over $55,583,851 and over the last 5 years he sold PRVL stock worth over $0. In addition, he makes $2,861,680 as President, Chief Executive Officer, and Director at Prevail Therapeutics Inc.
Asa has made over 1 trades of the Prevail Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 125,793 units of PRVL stock worth $1,237,803 on 30 December 2020.
The largest trade he's ever made was exercising 125,793 units of Prevail Therapeutics Inc stock on 30 December 2020 worth over $1,237,803. On average, Asa trades about 41,931 units every 0 days since 2020. As of 30 December 2020 he still owns at least 2,474,793 units of Prevail Therapeutics Inc stock.
You can see the complete history of Asa Abeliovich stock trades at the bottom of the page.
Dr. Asa Abeliovich M.D., Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Abeliovich has extensive industry expertise and more than 25 years of scientific, business and executive management experience in the biotechnology industry. Previously, he was a co-founder of Alector, Inc. and served as a consultant there from October 2013 to December 2017 and he also served as a tenured Associate Professor of Pathology, Cell Biology and Neurology at Columbia University and member of the Taub Institute for Alzheimer’s Disease and the Aging Brain from July 2000 to October 2017. He also served as an attending physician at Neurology at the New York-Presbyterian Hospital and the New York Psychiatric Institute. He is currently on the Scientific Advisory Board of the Silverstein Foundation for Parkinson’s with GBA. Dr. Abeliovich received an M.D. from Harvard Medical School, a Ph.D. from Massachusetts Institute of Technology, and bachelor degrees in Life Sciences and Humanities from the Massachusetts Institute of Technology. Abeliovich’s deep understanding of human genetics and his extensive scientific, business and executive management experience in the biotechnology industry make him particularly well-qualified to serve on our board of directors.
As the President, Chief Executive Officer, and Director of Prevail Therapeutics Inc, the total compensation of Asa Abeliovich at Prevail Therapeutics Inc is $2,861,680. There are no executives at Prevail Therapeutics Inc getting paid more.
Asa Abeliovich is 55, he's been the President, Chief Executive Officer, and Director of Prevail Therapeutics Inc since 2017. There are 6 older and 5 younger executives at Prevail Therapeutics Inc. The oldest executive at Prevail Therapeutics Inc is Franz Hefti, 72, who is the Chief Development Officer.
Asa's mailing address filed with the SEC is C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK, NY, 10016.
Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson, and Advisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.
Prevail Therapeutics Inc executives and other stock owners filed with the SEC include: